Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats

[1]  B. Baune,et al.  Neuroinflammation and cognition across psychiatric conditions , 2019, CNS Spectrums.

[2]  D. Boggs,et al.  The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial , 2018, Psychopharmacology.

[3]  D. Martins‐de‐Souza,et al.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia , 2018, European Archives of Psychiatry and Clinical Neuroscience.

[4]  P. McGuire,et al.  Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. , 2017, The American journal of psychiatry.

[5]  K. Mackie,et al.  Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment , 2017, Cannabis and cannabinoid research.

[6]  MurphyMichelle,et al.  Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment , 2017 .

[7]  S. Goldman,et al.  Human iPSC Glial Mouse Chimeras Reveal Glial Contributions to Schizophrenia. , 2017, Cell stem cell.

[8]  C. Paisán-Ruiz,et al.  Support for "Disease-Only" Genotypes and Excess of Homozygosity at the CYTH4 Primate-Specific GTTT-Repeat in Schizophrenia. , 2017, Genetic testing and molecular biomarkers.

[9]  M. Ikeda,et al.  Rare genetic variants in CX3CR1 and their contribution to the increased risk of schizophrenia and autism spectrum disorders , 2017, Translational Psychiatry.

[10]  Z. Vogel,et al.  Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid , 2017, International journal of molecular sciences.

[11]  J. Hallak,et al.  Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research , 2017, Front. Pharmacol..

[12]  N. Solowij,et al.  A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia , 2017, Neuroscience & Biobehavioral Reviews.

[13]  B. Pakkenberg,et al.  Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases , 2016, Scientific Reports.

[14]  F. Leweke,et al.  Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence , 2016, Front. Pharmacol..

[15]  M. Cuénod,et al.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? , 2016, Schizophrenia Research.

[16]  Benjamin A. Logsdon,et al.  Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia , 2016, Nature Neuroscience.

[17]  K. Mackie,et al.  An Introduction to the Endogenous Cannabinoid System , 2016, Biological Psychiatry.

[18]  Grayson O. Sipe,et al.  Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex , 2016, Nature Communications.

[19]  P. Shilling,et al.  A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia , 2016, Biological Psychiatry.

[20]  Giulio Genovese,et al.  Schizophrenia risk from complex variation of complement component 4 , 2016, Nature.

[21]  G. Riedel,et al.  MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol , 2015, Behavioural pharmacology.

[22]  Olga Peñagarikano,et al.  Endocannabinoid signaling mediates oxytocin-driven social reward , 2015, Proceedings of the National Academy of Sciences.

[23]  D. Blackburn,et al.  Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis , 2015, Front. Cell. Neurosci..

[24]  B. Pakkenberg,et al.  Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson’s Disease-like Dementia , 2015, Cell.

[25]  O. Blin,et al.  CX3CR1 is dysregulated in blood and brain from schizophrenia patients , 2015, Schizophrenia Research.

[26]  D. Sturdevant,et al.  Identification of Glial Activation Markers by Comparison of Transcriptome Changes between Astrocytes and Microglia following Innate Immune Stimulation , 2015, PloS one.

[27]  W. V. van Gool,et al.  Systemic inflammation and microglial activation: systematic review of animal experiments , 2015, Journal of Neuroinflammation.

[28]  F. Guimarães,et al.  Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine , 2015, Psychopharmacology.

[29]  F. Guimarães,et al.  Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol , 2015, Schizophrenia Research.

[30]  M. Tremblay,et al.  GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer’s disease , 2015, Brain, Behavior, and Immunity.

[31]  F. Leweke,et al.  Drug repurposing and emerging adjunctive treatments for schizophrenia , 2015, Expert opinion on pharmacotherapy.

[32]  M. Behmanesh,et al.  Dominant and Protective Role of the CYTH4 Primate-Specific GTTT-Repeat Longer Alleles Against Neurodegeneration , 2015, Journal of Molecular Neuroscience.

[33]  A. Teixeira,et al.  Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria , 2015, Neuroscience.

[34]  G. Coppola,et al.  Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells , 2015, Journal of Neuroinflammation.

[35]  V. Di Marzo,et al.  Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review , 2015, British journal of pharmacology.

[36]  K. Mirnics,et al.  Schizophrenia as a Disorder of Molecular Pathways , 2015, Biological Psychiatry.

[37]  Shannon E. Ellis,et al.  Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism , 2014, Nature Communications.

[38]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[39]  P. Skolnick,et al.  1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats , 2014, Psychopharmacology.

[40]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[41]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[42]  P. Allen,et al.  Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. , 2014, Current pharmaceutical design.

[43]  J. Hallak,et al.  Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain , 2014, Front. Pharmacol..

[44]  Francesco Sforazzini,et al.  Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior , 2014, Nature Neuroscience.

[45]  Yan Mei,et al.  The RNA-binding protein hnRNPLL induces a T cell alternative splicing program delineated by differential intron retention in polyadenylated RNA , 2014, Genome Biology.

[46]  S. Gygi,et al.  Identification of a Unique TGF-β Dependent Molecular and Functional Signature in Microglia , 2013, Nature Neuroscience.

[47]  Beth Stevens,et al.  TGF-β Signaling Regulates Neuronal C1q Expression and Developmental Synaptic Refinement , 2013, Nature Neuroscience.

[48]  D. Geschwind,et al.  Microarray and Pathway Analysis Reveal Distinct Mechanisms Underlying Cannabinoid-Mediated Modulation of LPS-Induced Activation of BV-2 Microglial Cells , 2013, PloS one.

[49]  Ben A. Barres,et al.  Emerging roles of astrocytes in neural circuit development , 2013, Nature Reviews Neuroscience.

[50]  F. Rosenbauer,et al.  Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways , 2013, Nature Neuroscience.

[51]  J. Quevedo,et al.  Immunopharmacology and inflammation Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis , 2012 .

[52]  Michael John Owen,et al.  Genome-Wide Association Study Implicates HLA-C*01:02 as a Risk Factor at the Major Histocompatibility Complex Locus in Schizophrenia , 2012, Biological Psychiatry.

[53]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance , 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[54]  Ben A. Barres,et al.  Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner , 2012, Neuron.

[55]  D. Geschwind,et al.  Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9‐tetrahydrocannabinol in BV‐2 microglial cells , 2012, British journal of pharmacology.

[56]  M. Hellmich,et al.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia , 2012, Translational Psychiatry.

[57]  N. Schröder,et al.  Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders , 2012, Psychopharmacology.

[58]  P. Popik,et al.  Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats , 2011, Psychopharmacology.

[59]  M. Giustetto,et al.  Synaptic Pruning by Microglia Is Necessary for Normal Brain Development , 2011, Science.

[60]  Jamaal A Rehman,et al.  TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease , 2011, Journal of Neuroinflammation.

[61]  Z. Vogel,et al.  Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis‐like disease in C57BL/6 mice , 2011, British journal of pharmacology.

[62]  H. Curran,et al.  Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being , 2011, Psychological Medicine.

[63]  A. M. Martín-Moreno,et al.  Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease , 2011, Molecular Pharmacology.

[64]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[65]  Z. Vogel,et al.  The Non-Psychoactive Plant Cannabinoid, Cannabidiol Affects Cholesterol Metabolism-Related Genes in Microglial Cells , 2011, Cellular and Molecular Neurobiology.

[66]  S. Rivest,et al.  CC Chemokine Receptor 2 Deficiency Aggravates Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[67]  R. Ophoff,et al.  Cannabis use at a young age is associated with psychotic experiences , 2010, Psychological Medicine.

[68]  J. Quevedo,et al.  Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture , 2010, Brain Research.

[69]  C. Morgan,et al.  Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis , 2010, Neuropsychopharmacology.

[70]  D. Prince,et al.  Enhanced synaptic connectivity and epilepsy in C1q knockout mice , 2010, Proceedings of the National Academy of Sciences.

[71]  T. Patterson,et al.  Gene expression profiling in the developing rat brain exposed to ketamine , 2010, Neuroscience.

[72]  J. Hallak,et al.  Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). , 2010, Revista brasileira de psiquiatria.

[73]  R. Murray,et al.  Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology , 2010, Neuropsychopharmacology.

[74]  Z. Vogel,et al.  Cannabinoids Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Inhibit the Lipopolysaccharide-activated NF-κB and Interferon-β/STAT Proinflammatory Pathways in BV-2 Microglial Cells* , 2009, The Journal of Biological Chemistry.

[75]  S. Dursun,et al.  Cannabidiol for the treatment of psychosis in Parkinson’s disease , 2009, Journal of psychopharmacology.

[76]  R. Murray,et al.  The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning , 2009, Psychological Medicine.

[77]  G. Juckel,et al.  Effects of acute oral Δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers , 2008, European Neuropsychopharmacology.

[78]  C. Morgan,et al.  Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis , 2008, British Journal of Psychiatry.

[79]  John D. Lambris,et al.  The Classical Complement Cascade Mediates CNS Synapse Elimination , 2007, Cell.

[80]  F. Guimarães,et al.  Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[81]  W. Gan,et al.  The P2Y12 receptor regulates microglial activation by extracellular nucleotides , 2006, Nature Neuroscience.

[82]  A. Zangen,et al.  Chronic exposure to Δ9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas , 2006, Molecular and Cellular Neuroscience.

[83]  D. Malone,et al.  Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice , 2006, Neuropsychopharmacology.

[84]  J. Julien,et al.  Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease , 2006, Neuron.

[85]  Peter B. Jones,et al.  Cannabis use and outcome of recent onset psychosis , 2005, European Psychiatry.

[86]  Ralitza Gueorguieva,et al.  Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction , 2005, Biological Psychiatry.

[87]  B. Morris,et al.  PCP: from pharmacology to modelling schizophrenia. , 2005, Current opinion in pharmacology.

[88]  Ralitza Gueorguieva,et al.  The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis , 2004, Neuropsychopharmacology.

[89]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[90]  F. Guimarães,et al.  Antipsychotic effect of cannabidiol. , 1995, The Journal of clinical psychiatry.

[91]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[92]  R. Mechoulam,et al.  Anandamide, a Brain Endogenous Compound, Interacts Specifically with Cannabinoid Receptors and Inhibits Adenylate Cyclase , 1993, Journal of neurochemistry.

[93]  P. Dingemans,et al.  Cannabis abuse and the course of recent onset schizophrenic disorders , 1993, Schizophrenia Research.

[94]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[95]  World federation of societies of biological psychiatry , 1990, Biological Psychiatry.

[96]  E. Carlini,et al.  Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. , 1974, European journal of pharmacology.

[97]  M. Pérez-Reyes,et al.  A comparison of the pharmacological activity in man of intravenously administered 1368-11368-11368-1, cannabinol, and cannabidiol , 1973, Experientia.

[98]  Brendan S. Whitelaw.  Microglia-mediated synaptic elimination in neuronal development and disease. , 2018, Journal of neurophysiology.

[99]  B. Garner,et al.  Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. , 2014, Journal of Alzheimer's disease : JAD.

[100]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[101]  P. Popik,et al.  Low doses of oxytocin facilitate social recognition in rats , 2005, Psychopharmacology.

[102]  A. Zuardi,et al.  Effects of cannabidiol in animal models predictive of antipsychotic activity , 2005, Psychopharmacology.

[103]  A. Zuardi,et al.  Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects , 2004, Psychopharmacology.

[104]  Andy P. Field,et al.  Discovering Statistics Using SPSS , 2000 .

[105]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .